Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — H1 2023 Earnings Presentation
17 slides from Expres2ion Biotech Holding Ab's earnings presentation, Aug 17, 2023
Slide 1: Presentation of 2023 Half-Year Results
Click to edit Master title style Presentation of 2023 Half-Year Results Innovative vaccines for a healthier world 17 August 2023 Hosted by Innovative vaccines for a healthier world
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of i
Slide 3: Strategic Review
Strategic Review • Strategic evaluation of ES2B-C001 • Certain activities to advance towards CTA readiness to continue, including the ongoing GLP preclinical safety toxicology study • Investigating strategic options • Initiating a cost reduction program • Near-term cash position enables us to mainta
Slide 4: Financial Results
Financial Results Innovative vaccines for a healthier world 4
Slide 5: Operating Income
FINANCE Operating Income Operating income, SEK ‘000s Net sales, SEK ‘000s Other operating income, SEK ‘000s 6.000 6.000 6.000 Net sales Other operating income 5.000 5.000 5.000 4.000 = 4.000 4.000 3.000 3.000 + 3.000 2.000 2.000 2.000 1.000 1.000 1.000 0 0 0 1Q20 3Q20 1Q21 3Q21 1Q22 3Q22 1Q23 1Q20 3
Slide 6: Operating Costs
FINANCE Operating Costs Operating costs, SEK ‘000s R&D costs (external), SEK ‘000s 0 0 -8.000 -5.000 -16.000 -10.000 -24.000 -15.000 -32.000 -20.000 -40.000 -25.000 -48.000 -30.000 -56.000 -35.000 -64.000 -40.000 1Q20 3Q20 1Q21 3Q21 1Q22 3Q22 1Q23 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q
Slide 7: Profit / Loss for the Period
FINANCE Profit / Loss for the Period 2Q profit / loss, SEK ‘000s YTD profit / loss, SEK ‘000s 2022 2023 2022 2023 0 0 -7.000 -12.000 -14.000 -24.000 -21.000 -36.000 -39.371 -25.535 +43% -28.000 -48.000 +18% -30.038 -56.346 -35.000 -60.000 Innovative vaccines for a healthier world 7
Slide 8: Cash Development Year-to-Date
FINANCE Cash Development Year-to-Date SEK millions 180 48 150 120 111 5 88 90 -76 60 30 0 December 2022 New Capital Operations and Investment Activities Currency changes June 2023 Innovative vaccines for a healthier world 8
Slide 9: Cash Balance, 2019 – 2Q 2023 Quarterly
FINANCE Cash Balance, 2019 – 2Q 2023 Quarterly SEK millions 200 175 168 150 150 142 139 125 125 107 108 111 100 88 83 75 72 50 30 25 13 10 6 5 3 5 0 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 Innovative vaccines for a healthier world 9
Slide 10: Management discussion and analysis
Management discussion and analysis 10 Innovative vaccines for a healthier world 10
Slide 11: Second Quarter Highlights
Second Quarter Highlights • ABNCoV2 • Discovery and Exploratory ✓ Positive readout for Phase II 12-month durability ✓ CMV on track ✓ Positive readout for Phase III non-inferiority to ✓ MucoVax initiated mRNA vaccine ❑ Further advancing exploratory vaccine pipeline ❑ Pending secondary endpoint for Ph
Slide 12: Pipeline
Pipeline Focus programs Pre-clinical Disease Project / Target Discovery Pharmacology cGMP / Tox Phase 1 Phase 2 Phase 3 Market potential COVID-19 ABNCoV2/SARS-CoV-2 cVLP > 10 billion EUR BREAST CANCER ES2B-C001/Her2 cVLP > 10 billion EUR INFLUENZA MucoVax > 7 billion EUR CMV ES2B-I002 > 2 billion EU
Slide 13: Pipeline
Pipeline Legacy programs Pre-clinical Disease Project / Target Discovery Pharmacology cGMP / Tox Phase 1 Phase 2 Phase 3 Market potential MALARIA >1.8 billion EUR 1: Blood-Stage RH5 2: Blood-Stage RH5-VLP 3: Transmission Pfs 48/45 4: Placenta-Borne VAR2CSA 5: Blood-Stage CYRPA complex INFLUENZA INDI
Slide 14: ABNCoV2 – Proof-of-concept for S2 and VLP
CORONAVIRUS E X P R E S2 I O N ABNCoV2 – BIOTECHNOLOGIES Proof-of-concept for S2 and VLP Phase III primary endpoint: Non- Greater durability than approved inferiority to Pfizer mRNA vaccine vaccines across variants of concern Strong boosting effect across Stability at room temperature variants of co
Slide 15: Potential income from ABNCoV2
CORONAVIRUS Potential income from ABNCoV2 AdaptVac receives from Bavarian Nordic ExpreS2ion receives from AdaptVac • EUR 4 million upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to EUR 136 million in development and • Up to EUR 2 million in commercial milestone sales milestones payment
Slide 16: Advancing focus pipeline towards key catalysts
Advancing focus pipeline towards key catalysts 2022 2023 2024 2025+ ✓ ✓ ✓ BN Phase II 12-month durability data BN BN Phase II trial BN Phase III trial ✓ Phase III initial readout readout H1 initiation Q3 COVID-19 Phase III secondary readout Potential royalties ABNCoV2 from sales BN potentially initi
Slide 17: Thank you
Thank you investor@expres2ionbio.com Innovative vaccines for a healthier world 17
ExpreS2ion Biotech Holding — H1 2023 Earnings Presentation on 6ix